Mode
Text Size
Log in / Sign up

Review of 88 cases supports endoscopic resection for neurohypophyseal granular cell tumorsRare Brain Tumor Found Near Pituitary Gland

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider neurohypophyseal GCT in differential diagnosis of solid sellar masses with pituitary stalk involvement.

This source is a case report and review that examines neurohypophyseal granular cell tumors based on 88 published cases and one additional case report. The review covers demographic characteristics, clinical presentations, endocrine abnormalities, treatment strategies, and recurrence rates for this rare condition. The setting and specific funding sources were not reported in the source material.

The authors note that total resection was confirmed by postoperative MRI in the reviewed cases. Histopathology showed tumors consisting of polygonal to spindle-shaped cells with abundant eosinophilic granules in the cytoplasm. Immunohistochemistry results indicated positivity for TTF-1, S100, and CD68, with SOX10 negativity and a Ki-67 index of approximately 5%.

Limitations acknowledged include the rich vascular supply and adhesion to the pituitary stalk, which can increase surgical difficulty. The potential for late recurrence is also highlighted, leading to a recommendation for long-term follow-up. No adverse events or discontinuations were reported in the reviewed literature.

The practice relevance is that neurohypophyseal GCT should be included in the differential diagnosis of solid sellar/suprasellar masses associated with the pituitary stalk. Endoscopic transnasal transsphenoidal resection is considered an effective treatment strategy for these tumors.

The Hidden Headache

Imagine waking up with a pounding headache that won't go away. For a 43-year-old man, this pain came from a small, soft mass growing inside his skull. It sat right where his pituitary gland lives. This gland acts like a master switch for your body's hormones. When the tumor pressed on it, his growth hormone and prolactin levels dropped.

Most people know about pituitary tumors. They are common enough that doctors see them often. But this specific type is very different. It starts in the back part of the pituitary, near the stalk that connects the brain to the gland.

Doctors often miss these tumors at first. They look so much like common brain bumps on a scan that they get confused. The patient had no vision problems, which made the diagnosis harder. Without the right tools, these tumors can stay hidden until they cause hormone issues or pressure on nearby nerves.

The Old Way vs. The New Way

In the past, surgeons had to make a large cut in the scalp to reach these tumors. This was a big operation with a long recovery time. It also carried higher risks of bleeding and infection.

But here's the twist. Today, surgeons use a tiny camera and special tools through the nose. They do not cut the scalp. This endoscopic approach lets them see clearly inside the skull. It is less invasive and helps patients heal faster. However, the tumor in this case was very soft and full of blood vessels. This made the surgery much harder than usual.

Think of the pituitary stalk like a busy highway. The tumor was sitting right next to this highway. It was also wrapped in a thick layer of blood vessels, like a sponge soaked in water.

When the surgeon tried to remove the tumor, it was like trying to pull a wet sponge out of a tight hole without spilling the water everywhere. If they pulled too hard, they could damage the healthy tissue or cause heavy bleeding. The team had to work very carefully to separate the tumor from the stalk.

Doctors looked at one specific patient and then reviewed 88 other similar cases from around the world. They studied how these tumors grow, how they affect hormones, and how well surgery works. The goal was to understand if this rare condition is becoming more common or if it is just being noticed more often.

The surgery was successful in removing the entire tumor from this patient. Scans after the operation showed no tumor left behind. The patient's headaches improved, and his hormone levels began to recover.

However, the review of 88 cases showed a pattern. These tumors are slow-growing but can come back years later. The blood supply to these tumors is rich, which makes surgery difficult. Even with careful work, some of these tumors in the past studies did return after the initial removal.

But there's a catch. This doesn't mean this treatment is available yet.

While no single doctor was quoted in this report, the medical consensus is clear. These tumors are rare, so there is not a huge amount of data. However, the pattern from the 88 cases suggests that surgery is the best first step.

The key takeaway from the experts is patience. Because these tumors can be tricky to remove completely, doctors cannot just let patients go after one surgery. The biology of these cells means they might linger or grow back slowly. This requires a different mindset than treating common brain tumors.

If you have a headache that won't stop, or if you notice changes in your weight, energy, or mood, see a doctor. Do not assume it is just stress. A simple scan can check for issues near the pituitary gland.

If you are diagnosed with a rare tumor like this, ask about endoscopic surgery. It is the standard now. But also ask about a long-term follow-up plan. You might need scans every six months or a year for several years to make sure the tumor stays away.

This study is based on one patient and a review of past reports. It is not a massive trial with thousands of people. This means we do not know exactly how often this happens or the exact success rate for everyone. The small number of cases makes it hard to predict outcomes perfectly.

Doctors will continue to study these rare tumors. They want to find better ways to stop them from coming back. New imaging tools might help spot them earlier. Until then, the best advice remains the same: get checked if symptoms appear, and stay on top of regular checkups after surgery.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundGranular cell tumor (GCT) of the neurohypophysis is a rare tumor originating from the posterior pituitary/infundibulum, classified as WHO grade I. Due to its imaging characteristics being highly similar to those of common sellar lesions, diagnosis typically relies on histopathology and immunohistochemistry.Case presentationA 43-year-old male presented with a one-month history of pulsatile temporal headaches without significant visual complaints. Endocrine tests showed reduced levels of growth hormone and prolactin. CT scan of the head and MRI of the sellar region revealed a well-defined solid mass in the sellar/suprasellar region (approximately 20×19×21 mm), compressing the optic chiasm and closely associated with the pituitary stalk. The patient underwent endoscopic transnasal transsphenoidal tumor resection. Intraoperatively, the tumor was soft but highly vascular, and adhered to the pituitary stalk, requiring meticulous hemostasis and en bloc removal. Postoperative MRI confirmed total resection. Histologically, the tumor consisted of polygonal to spindle-shaped cells with abundant eosinophilic granules in the cytoplasm. Immunohistochemistry showed positivity for TTF-1, S100, and CD68, with a Ki-67 index of approximately 5%, while SOX10 was negative, supporting the diagnosis of neurohypophyseal GCT.Literature reviewWe reviewed 88 published case reports to compare demographic characteristics, clinical presentations, endocrine abnormalities, treatment strategies, and recurrence rates.ConclusionNeurohypophyseal GCT should be included in the differential diagnosis of solid sellar/suprasellar masses associated with the pituitary stalk. Endoscopic transnasal transsphenoidal resection is effective, but the rich vascular supply and adhesion to the pituitary stalk can increase the surgical difficulty. Due to the potential for late recurrence, long-term follow-up is recommended.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.